Sandoz Lays Out Plan For Rebound With Top Line Stagnant In 2021
Core Operating Profit Falls By 12% As Reported; 14% In Constant Currencies
Novartis admits that its Sandoz division is not expected to enjoy turnover growth in 2022, due to a lack of material launches, but is planning for a rise in 2023 and beyond.
